Cingulate shares surge 10.48% premarket following positive Phase 3 trial results for ADHD drug CTx-1301.

Cingulate Inc. surged 10.48% in premarket trading following the announcement that it will present at the LD Micro Main Event XVI, a prominent investor conference for early-stage biotech firms. This event, scheduled for September 21, provides the company with a platform to highlight its ADHD drug candidate CTx-1301, which recently demonstrated positive Phase 3 trial results for adult patients. The presentation aligns with ongoing efforts to advance regulatory and commercialization milestones for its lead product, bolstering investor confidence. Earlier in September, Cingulate also expanded its at-the-market equity offering capacity, signaling strategic capital-raising flexibility. These developments collectively reinforce the stock’s upward momentum ahead of the conference.